Payment overview · 2025
General Payments
$1,233.22
62 reported records · 22 companies
Healthcare provider profile · identity verified
Michael E Debs, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORTH ROYALTON, OH · NPI 1063486082
Verified facts
What the public records show
CMS Open Payments records show Michael E Debs, MD received $1,233.22 in general payments during 2025 across 62 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $175.57 | 14.2% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $118.48 | 9.6% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $115.83 | 9.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.29 | 7.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $89.35 | 7.2% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $75.72 | 6.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $66.76 | 5.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.89 | 4.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.12 | 4.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.40 | 3.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.78 | 3.5% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $42.05 | 3.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.42 | 3.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $39.81 | 3.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.08 | 2.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $32.85 | 2.7% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.77 | 1.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.20 | 1.9% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $19.36 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.01 | 1.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.51 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.97 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,233.22 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $194.57 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $99.48 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $99.48 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $89.35 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $80.48 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $75.72 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.15 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $66.76 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.27 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.69 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.12 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.12 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.78 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.42 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $39.81 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $32.85 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $28.61 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 376 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 174 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
81 | 25 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
174 | 32 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
376 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
101 | 20 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
81 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
174 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
376 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1399 | 321 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1300 | 315 |
| Levothyroxine Sodium | Levothyroxine Sodium | 960 | 205 |
| Losartan Potassium | Losartan Potassium | 639 | 160 |
| Metoprolol Succinate | Metoprolol Succinate | 627 | 150 |
| Pantoprazole Sodium | Pantoprazole Sodium | 551 | 128 |
| Simvastatin | Simvastatin | 529 | 114 |
| Lisinopril | Lisinopril | 443 | 119 |
| Metformin Hcl | Metformin Hcl | 437 | 118 |
| Hydrochlorothiazide | Hydrochlorothiazide | 422 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 394 | 99 |
| Escitalopram Oxalate | Escitalopram Oxalate | 389 | 101 |
| Furosemide | Furosemide | 389 | 109 |
| Eliquis | Apixaban | 376 | 62 |
| Sertraline Hcl | Sertraline Hcl | 376 | 74 |
| Glimepiride | Glimepiride | 364 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 338 | 82 |
| Gabapentin | Gabapentin | 302 | 62 |
| Mirtazapine | Mirtazapine | 257 | 49 |
| Doxazosin Mesylate | Doxazosin Mesylate | 254 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 252 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 249 | 65 |
| Trazodone Hcl | Trazodone Hcl | 246 | 60 |
| Allopurinol | Allopurinol | 240 | 50 |
| Alendronate Sodium | Alendronate Sodium | 239 | 49 |
| Donepezil Hcl | Donepezil Hcl | 217 | 30 |
| Potassium Chloride | Potassium Chloride | 201 | 52 |
| Omeprazole | Omeprazole | 192 | 51 |
| Azithromycin | Azithromycin | 179 | 146 |
| Jardiance | Empagliflozin | 174 | 32 |
| Memantine Hcl | Memantine Hcl | 174 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 171 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 159 | 37 |
| Ezetimibe | Ezetimibe | 146 | 40 |
| Methylprednisolone | Methylprednisolone | 136 | 110 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 38 |
| Torsemide | Torsemide | 126 | 44 |
| Spironolactone | Spironolactone | 124 | 28 |
| Alprazolam | Alprazolam | 119 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 31 |
| Tramadol Hcl | Tramadol Hcl | 115 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 47 |
| Ozempic | Semaglutide | 109 | 25 |
| Atenolol | Atenolol | 108 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 31 |
| Carvedilol | Carvedilol | 101 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 78 |
| Levofloxacin | Levofloxacin | 99 | 71 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 95 | 15 |
| Trulicity | Dulaglutide | 94 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 93 | 24 |
| Metformin Hcl Er | Metformin Hcl | 91 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 60 |
| Glipizide | Glipizide | 87 | 20 |
| Famotidine | Famotidine | 85 | 15 |
| Risperidone | Risperidone | 85 | 13 |
| Prednisone | Prednisone | 82 | 33 |
| Synthroid | Levothyroxine Sodium | 81 | 25 |
| Xarelto | Rivaroxaban | 81 | 14 |
| Lorazepam | Lorazepam | 77 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 75 | 13 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 73 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 15 |
| Montelukast Sodium | Montelukast Sodium | 71 | 27 |
| Pregabalin | Pregabalin | 71 | 19 |
| Bupropion Xl | Bupropion Hcl | 69 | 16 |
| Divalproex Sodium | Divalproex Sodium | 69 | 13 |
| Warfarin Sodium | Warfarin Sodium | 68 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 11 |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 17 |
| Celecoxib | Celecoxib | 61 | 19 |
| Meloxicam | Meloxicam | 61 | 16 |
| Cephalexin | Cephalexin | 60 | 35 |
| Benazepril Hcl | Benazepril Hcl | 58 | suppressed |
| Myrbetriq | Mirabegron | 58 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 16 |
| Lovastatin | Lovastatin | 48 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 47 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 26 |
| Diazepam | Diazepam | 46 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 46 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 13 |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 31 |
| Lansoprazole | Lansoprazole | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 39 | 11 |
| Latanoprost | Latanoprost | 38 | 11 |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 13 |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 11 |
| Nystatin | Nystatin | 34 | 23 |
| Colchicine | Colchicine | 33 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 32 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 14 |
| Valsartan | Valsartan | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 28 | suppressed |
| Rivastigmine | Rivastigmine | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Prolia | Denosumab | 24 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Tobramycin | Tobramycin | 23 | 15 |
| Valacyclovir | Valacyclovir Hcl | 23 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 16 |
| Topiramate | Topiramate | 22 | suppressed |
| Ivermectin | Ivermectin | 21 | 15 |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 12 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 11 |
| Telmisartan | Telmisartan | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Cyclosporine | Cyclosporine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Acyclovir | Acyclovir | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Permethrin | Permethrin | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | 12 |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Lamictal Xr | Lamotrigine | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,233.22 · 62 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, CAMZYOS, CAPVAXIVE, CHARTIS CATHETER, CREON, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, INSPIRE, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, REPATHA, REXULTI, SPRAVATO, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error